Vivani Medical(US:VANI)2026-03-26 20:36Financial Performance - Vivani Medical reported a net loss of $26.6 million for the full year 2025, an increase of 13.2% compared to a net loss of $23.5 million in 2024[18]. - Net loss for 2025 was $26,609 thousand, compared to a net loss of $23,486 thousand in 2024, indicating a worsening of approximately 13.0%[27]. - Net loss per common share remained at $0.43 for both 2024 and 2025, indicating consistent performance in terms of loss per share[27]. Expenses - Research and development expenses for the year ended December 31, 2025, were $18.1 million, reflecting a 15% increase from $15.7 million in 2024[15]. - General and administrative expenses for the full year 2025 were $9.4 million, a 6% increase from $8.9 million in 2024[16]. - Total operating expenses increased from $24,677 thousand in 2024 to $27,556 thousand in 2025, representing an increase of about 11.5%[27]. - Research and development expenses rose from $15,745 thousand in 2024 to $18,126 thousand in 2025, an increase of about 15.1%[27]. - General and administrative expenses increased from $8,932 thousand in 2024 to $9,430 thousand in 2025, reflecting a rise of approximately 5.6%[27]. Cash and Assets - As of December 31, 2025, Vivani had cash and cash equivalents of $16.2 million, down from $18.4 million at the end of 2024[11]. - Total current assets decreased from $20,442 thousand in 2024 to $17,898 thousand in 2025, a decline of approximately 12.5%[25]. - Cash and cash equivalents decreased from $18,352 thousand in 2024 to $16,232 thousand in 2025, a decline of approximately 11.6%[25]. Liabilities and Equity - Total liabilities decreased slightly from $23,951 thousand in 2024 to $23,663 thousand in 2025, a reduction of about 1.2%[25]. - Total stockholders' equity decreased from $17,610 thousand in 2024 to $15,730 thousand in 2025, a decline of approximately 10.7%[25]. Financing and Future Plans - The company raised $41.5 million in gross proceeds through multiple financing activities in 2025 and 2026, supporting operations into mid-2027[8]. - The company plans to transition Cortigent into an independent publicly traded company, exploring both a spin-off and an IPO[20]. Clinical Studies and Product Development - The Phase 1 clinical study for NPM-139, a semaglutide implant for chronic weight management, is projected to begin in mid-2026, with results expected by the end of 2026[4]. - The LIBERATE-1 study demonstrated over 20% sham-adjusted weight loss sustained for a full year with a single administration of the semaglutide implant[2]. - Significant progress has been made in manufacturing capabilities to prepare for commercial-scale production of the semaglutide implant[4].